NASDAQ: RPIDRapid Micro Biosystems Inc Stock
$2.31+0.01 (+0.43%)
Updated Apr 23, 2025
RPID Price
$2.31
Fair Value Price
N/A
Market Cap
$99.88M
52 Week Low
$0.58
52 Week High
$4.04
P/E
-2.14x
P/B
1.33x
P/S
1.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.05M
Earnings
-$46.89M
Gross Margin
-0.4%
Operating Margin
-178.36%
Profit Margin
-167.2%
Debt to Equity
0.3
Operating Cash Flow
-$44M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RPID Overview
Rapid Micro Biosystems Incorporated offers automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship platform, Growth Direct, automates manual microbial quality control (MQC), testing workflows used in pharmaceutical manufacturing operations. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. Rapid Micro Biosystems was incorporated in 2006 and is headquartered in Lowell, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RPID's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
RPID
Ranked#65 of 104
Ranked#65 of 104
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.59 | A | |
| $22.81 | A | |
| $14.03 | A |
Be the first to know about important RPID news, forecast changes, insider trades & much more!
RPID News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RPID scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPID is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RPID is good value based on its book value relative to its share price (1.33x), compared to the US Medical Devices industry average (3.85x)
P/B vs Industry Valuation
RPID is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RPID due diligence checks available for Premium users.
Valuation
RPID price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.14x
Industry
35.78x
Market
26.95x
RPID price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.33x
Industry
3.85x
RPID is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPID's financial health
Profit margin
Revenue
$8.2M
Net Income
-$9.7M
Profit Margin
-117.6%
RPID's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RPID's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$98.2M
Liabilities
$22.8M
Debt to equity
0.3
RPID's short-term assets ($80.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPID's short-term assets ($80.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPID's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RPID's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
$4.9M
Financing
-$6.0k
RPID's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RPID vs Medical Device Stocks
Rapid Micro Biosystems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.